These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36580154)

  • 1. Serum and vitreous vascular endothelial growth factor levels in diabetic retinopathy.
    Sozen-Delil FI; Cekic O; Haklar G
    Int Ophthalmol; 2023 Jul; 43(7):2247-2255. PubMed ID: 36580154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of ranibizumab on the level of intercellular adhesion molecule type 1 in the vitreous of eyes with proliferative diabetic retinopathy.
    Yan Y; Zhu L; Hong L; Deng J; Song Y; Chen X
    Acta Ophthalmol; 2016 Jun; 94(4):358-64. PubMed ID: 26285163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
    Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
    Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
    Ma Y; Zhang Y; Zhao T; Jiang YR
    Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage.
    Li S; Yang Y; Zou J; Zeng J; Ding C
    BMC Ophthalmol; 2022 Feb; 22(1):63. PubMed ID: 35139812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
    Qian J; Lu Q; Tao Y; Jiang YR
    Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of before versus after intravitreal bevacizumab injection, growth factor levels and fibrotic markers in vitreous samples from patients with proliferative diabetic retinopathy.
    Ozer F; Tokuc EO; Albayrak MGB; Akpinar G; Kasap M; Karabas VL
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1899-1906. PubMed ID: 35028761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy.
    Li B; Li MD; Ye JJ; Chen Z; Guo ZJ; Di Y
    Chin Med J (Engl); 2020 Mar; 133(6):664-669. PubMed ID: 32068603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab.
    Li JK; Wei F; Jin XH; Dai YM; Cui HS; Li YM
    Int J Ophthalmol; 2015; 8(6):1202-6. PubMed ID: 26682173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-sectional study of vitreous and serum high mobility group box-1 levels in proliferative diabetic retinopathy.
    Shen Y; Cao H; Chen F; Suo Y; Wang N; Xu X
    Acta Ophthalmol; 2020 Mar; 98(2):e212-e216. PubMed ID: 31421026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy.
    Cancarini A; Costagliola C; Dell'omo R; Romano M; Morescalchi F; Agnifili L; Ruggeri G; Semeraro F
    Minerva Endocrinol; 2014 Dec; 39(4):305-11. PubMed ID: 25371057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.
    Matsumoto M; Suzuma K; Maki T; Kinoshita H; Tsuiki E; Fujikawa A; Kitaoka T
    Am J Ophthalmol; 2012 May; 153(5):896-902.e1. PubMed ID: 22265145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1.
    Sohn EH; He S; Kim LA; Salehi-Had H; Javaheri M; Spee C; Dustin L; Hinton DR; Eliott D
    Arch Ophthalmol; 2012 Sep; 130(9):1127-34. PubMed ID: 22965588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
    Itakura H; Kishi S; Kotajima N; Murakami M
    Ophthalmology; 2004 Oct; 111(10):1880-4. PubMed ID: 15465550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
    Watanabe D; Suzuma K; Suzuma I; Ohashi H; Ojima T; Kurimoto M; Murakami T; Kimura T; Takagi H
    Am J Ophthalmol; 2005 Mar; 139(3):476-81. PubMed ID: 15767056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy.
    Wang X; Wang G; Wang Y
    Am J Ophthalmol; 2009 Dec; 148(6):883-9. PubMed ID: 19837381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy.
    Simó R; Lecube A; Segura RM; García Arumí J; Hernández C
    Am J Ophthalmol; 2002 Sep; 134(3):376-82. PubMed ID: 12208249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ANGPTL-4 correlates with vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
    Lu Q; Zou W; Chen B; Zou C; Zhao M; Zheng Z
    Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1281-8. PubMed ID: 26483143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitreous Fibronectin and Fibrinogen Expression Increased in Eyes With Proliferative Diabetic Retinopathy After Intravitreal Anti-VEGF Therapy.
    Wei Q; Zhang T; Jiang R; Chang Q; Zhang Y; Huang X; Gao X; Jin H; Xu G
    Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5783-5791. PubMed ID: 29117316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.
    Citirik M; Kabatas EU; Batman C; Akin KO; Kabatas N
    Ophthalmic Res; 2012; 47(1):7-12. PubMed ID: 21691136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.